#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

For decades, genetic medicine could only reliably reach the liver, but we’re now showing tumor-to-tumor immune ripple effects that clear deep-organ metastases in multiple patients, not just skin lesions. It feels like the edge of a real shift where many cancers become manageable instead of fatal.

Welcome to an experiment: part interview, part live jam session with a founder I’m betting on, where you’ll hear raw brainstorming that later helped shape talking points all the way up to the highest levels in DC. I’ll share why I’m excited about Strand, how the message evolved, and I’d love feedback on how to make this format even better.

Strand builds next‑gen genetic medicines by sending RNA instructions to the right cells so they make the right proteins, where and when they’re needed. The goal is simple: restore cellular balance or, in cancer, flip the switch that helps the body eliminate the threat.

We first met at a Boston dinner, and what grabbed me was the tech, the images, and that you’re a mission-first founder taking bold, thoughtful swings. Let’s start with the image you showed me—what were we looking at?

It was a stage‑four melanoma patient who’d exhausted options, including top immunotherapies, with tumors across skin and vital organs, and then a follow‑up scan with no detectable lesions. Beyond the data, that moment landed for me as a scientist because it meant someone’s grandparent got real time back.

In your deck, what resonated most for non‑specialists beyond the images—what made the stakes tangible?

Survival curves can look abstract, so I translate each step as a life extended or lost, then draw a hard line between a good drug and a good product. For example, ex vivo cell therapies can save lives yet remain slow and wildly expensive, so we’re pushing in‑body reprogramming you can run through an IV in a normal infusion visit.

For the layperson, what did treatment look like for the patient in those images?

Instead of just blocking tumor “don’t attack me” signals, we deliver RNA instructions that make the tumor broadcast danger the immune system can’t ignore. We inject an accessible lesion, the immune system clears it, learns the signature, and then hunts down distant tumors.

So you’re provoking an abscopal effect, and in this case it reached visceral sites; is that new ground in practice?

Abscopal effects have been seen, but usually locally; we’re seeing unusually broad responses into organs across multiple patients, even early in a phase one. To reach more people, the next leap is IV delivery that fits infusion‑clinic workflows, breaking out of the 30‑year trap where genetic medicines mostly end up in the liver, and that means solving not just vehicles but potency and specificity together.

If I were shaping a TED‑style talk, I’d open with the patient story and scan, then use the SpaceX platform analogy to show why delivery that plugs into healthcare wins, even if the science is dazzling. Who most needs to hear this now?

Policy leaders worldwide, because they define what’s allowed and what gets paid for. Medicine’s moving toward many targeted variants, so rules and reimbursement need to flex while we build products that fit today’s care settings.

What’s your concrete ask if a policymaker can greenlight one thing right now?

Streamline first‑in‑human trials by shifting to an IRB‑driven clinical‑trial notification model like Australia’s, instead of massive upfront FDA permissions that take ages and millions. That cuts time and cost, opens access beyond a few elite centers, and lets the FDA focus on judging safety and efficacy at approval.

How feasible is that here, and what’s the global competitive pressure?

China’s built a fast, industrialized engine for early trials and capital follows speed, so we’re at risk of falling behind if we don’t adapt. I think there’s a real shot at CTN‑style reform within a couple of years, and allies like the UAE are eager to move quickly and partner.

On your platform story, are you leaning into or away from the word programming?

I avoid that term and define platforms by target tissue—tumor delivery is one, T‑cell delivery is another—and we advance them stepwise, like Falcon before Starship. The first drug proves the platform; then we swap payloads and expand to tougher destinations.

Two months later, your op‑ed lands, we split‑test headlines, you testify on the Hill, and the message reaches the top; what unfolded after publishing?

The piece spread fast in biotech and policy circles, led to a congressional hearing invite, and we reframed the story as an urgent but fixable opportunity, not just a warning. Weeks later, the President’s legislative priorities explicitly called for easing early‑stage FDA barriers so Americans can access experimental medicines here.

We tested framing to boost click‑through and shape your live remarks; where does the messaging sit now?

Leading with a clear solution unlocked traction, and the big lesson holds: make people care first, then walk them through the details.

Working headline is RNA medicine and the rise of platform therapeutics.

I want to introduce what a therapeutic platform really is, why it changes how we invent and deploy drugs across the next year, five years, and the next decade, and why policy has to evolve to keep up. Think space and rockets: long timelines, high upfront costs, and binary outcomes, which means we need smarter, faster regulatory paths without compromising safety.

Most biotech has been one‑drug‑at‑a‑time, which resets risk each time and shares know‑how publicly. A platform builds common tech you can reuse, like Moderna’s mRNA engine that plugged in a new sequence after years of groundwork, enabling speed when it mattered.

Think Uber building everything for delivery, then swapping in a new payload. When people say it took 60 days, it only worked because the rails were already there.

To realize the future, we need two things: new programmable therapies and the physical systems to make and deliver them everywhere. We’re solving delivery like rockets and payloads, because AI is exploding discovery, and the bottleneck is shifting to getting the right protein to the right tissue at scale.

As CEO, what’s actually blocking you from doing this?

Capital markets reward incremental assets you flip to pharma, not bold, multi‑product platforms. The industry behaves like real estate development, moving ideas from A to a partial B and selling, which works for small wins but starves generational builders.

So what would a SpaceX‑style shift look like, and why does it matter?

It’s about capital formation and storytelling that align patient money with long‑term missions. You have to gather serious dollars around a vision that only pays off after multiple shots on goal.

Our job is to find partners who want 10 to 30‑year outcomes, not next‑year IRR. We need to make the plan legible—everyone wants cures, but we have to show the road from today’s wins to solving disease at large.

Do you go public with the plan and court bigger, longer‑term pools, or work with sovereign funds now? What are the key dominoes?

I look at Bezos: say what you’re building, say it often, and execute in plain view until value catches up. You repeat the mission so you do not take the easy off‑ramp, and you remember you are not your market cap.

Great investors back companies in the post‑conviction, pre‑consensus window. You know it works internally; the world has not priced it yet. Our task is to reach that consensus through results and clear communication.

The Moderna story lands, but it’s become politicized. Is there a cleaner analogy?

Insulin is the origin story: moving from pig pancreas to recombinant production birthed a platform that enabled antibodies and more. Then pharma consolidated, M&A became the exit, and biotech optimized for being acquired, to the point public markets often bet against small companies launching their own drugs. That’s how we drifted from platform ambition to pipeline arbitrage.

Any modern parallels to how you’re thinking, beyond rockets?

Apple rebuilt around the iPhone as a delivery platform that kept improving and unlocked an ecosystem. In medicine, the analogous win is reliable delivery of the right protein to any cell. Near term it powers better drugs and faster trials; over time it enables personalization once manufacturing and clinical logistics make bespoke therapies viable.

The Baby KJ case shows personalized editing can save a life when the target is in the liver, but many diseases sit in other tissues. We have to crack delivery across the body and build the infrastructure so personalization is not a one‑off miracle but scalable care.

We’ll link to Baby KJ for folks curious about that first personalized systemic edit. This was super fun—great to see you, and I’m here if I can help.

Always a blast talking with you, Tim. Take care.